Benzinga's Top #PreMarket Gainers

Furiex Pharmaceuticals (NASDAQ: FURX ) soared 93.85% to $88.88 in the pre-market trading on positive top-line results from two pivotal Phase III clinical trials of eluxadoline for IBS-d. ATMI (NASDAQ: ATMI ) shares gained 25.32% to $33.75 in the pre-market after the company reported upbeat Q4 earnings. Entegris